New targeted therapy could bring relief to people with lichen planus
Mayo Clinic researchers have identified a targeted therapy that could bring relief to people living with lichen planus, a ...
FDA Approves Expanded Access Program For Lipella Pharma's LP-310 In Oral Lichen Planus; Stock Up
Lipella Pharmaceuticals Inc. (LIPO), a clinical-stage biotechnology company, Wednesday said that the U.S. Food and Drug ...
Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus
The FDA’s approval for expanded use reinforces LP-310’s potential as a new therapeutic option for OLP and supports ongoing clinical development efforts.